These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9250542)

  • 1. Pharmacogenetics and heart failure: a convergence with carvedilol.
    Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
    Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
    [No Abstract]   [Full Text] [Related]  

  • 2. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
    Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
    J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Carvedilol in cardiac decompensation].
    Dib J
    Rev Med Liege; 1996 Feb; 51(2):198-200. PubMed ID: 8650455
    [No Abstract]   [Full Text] [Related]  

  • 4. [Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].
    Wuttke H; Rau T; Eschenhagen T
    Dtsch Med Wochenschr; 2004 Apr; 129(15):831-5. PubMed ID: 15054690
    [No Abstract]   [Full Text] [Related]  

  • 5. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
    Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
    Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH; Wood AJ
    Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
    Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
    J Pharm Pharm Sci; 2006; 9(1):101-12. PubMed ID: 16849011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure and the therapy of advanced heart failure.
    Cohn JN
    J Am Coll Cardiol; 2004 Apr; 43(8):1430-1. PubMed ID: 15093879
    [No Abstract]   [Full Text] [Related]  

  • 9. Major heart failure news from 2001.
    Francis D
    Heart Fail Monit; 2002; 2(4):147-8. PubMed ID: 12638556
    [No Abstract]   [Full Text] [Related]  

  • 10. [Carvedilol and heart failure: new findings].
    Cosín Aguilar J
    Rev Esp Cardiol; 1996 Feb; 49(2):85-7. PubMed ID: 8948716
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using carvedilol to treat heart failure.
    Taccetta-Chapnick M
    Crit Care Nurse; 2002 Apr; 22(2):36-40, 42-6, 48 passim. PubMed ID: 11961943
    [No Abstract]   [Full Text] [Related]  

  • 13. Carvedilol for heart failure.
    Med Lett Drugs Ther; 1997 Sep; 39(1010):89-91. PubMed ID: 9323960
    [No Abstract]   [Full Text] [Related]  

  • 14. [The optimal treatment of chronic heart failure with beta-blockers may be dependent upon the genetic background of the patient].
    Leschot NJ; Wilde AA
    Ned Tijdschr Geneeskd; 2007 Jul; 151(29):1610-1. PubMed ID: 17727180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Carvedilol].
    Antepohl W; Herzig S; Böhm M
    Dtsch Med Wochenschr; 1997 Jun; 122(25-26):833-4. PubMed ID: 9244672
    [No Abstract]   [Full Text] [Related]  

  • 16. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
    Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
    Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carvedilol.
    Frishman WH
    Indian Heart J; 1999; 51(3):325-32. PubMed ID: 10624077
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy with beta blockers in heart failure. Recent studies of carvedilol].
    Böhm M; Erdmann E
    Fortschr Med; 1996 May; 114(13):167-8. PubMed ID: 8964561
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
    DasGupta P; Broadhurst P; Lahiri A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol.
    Frishman WH
    N Engl J Med; 1998 Dec; 339(24):1759-65. PubMed ID: 9845712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.